Alpharma Revenue and Competitors
Estimated Revenue & Valuation
- Alpharma's estimated annual revenue is currently $142.1M per year.
- Alpharma's estimated revenue per employee is $201,000
Employee Data
- Alpharma has 707 Employees.
- Alpharma grew their employee count by 7% last year.
Alpharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Manager, Global Engineering | Reveal Email/Phone |
2 | Lab Asst | Reveal Email/Phone |
3 | Executive Asst./Corp. Finance Coordinator | Reveal Email/Phone |
Alpharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.6M | 33 | 32% | N/A | N/A |
#2 | $38M | 189 | 6% | N/A | N/A |
#3 | $6.6M | 33 | 22% | N/A | N/A |
#4 | $4180M | 15242 | 1% | $550M | N/A |
#5 | $17.5M | 87 | 50% | N/A | N/A |
#6 | $6.7M | 125 | -37% | $199.6M | N/A |
#7 | $10.9M | 54 | 15% | N/A | N/A |
#8 | $15.3M | 76 | 33% | N/A | N/A |
#9 | $128.6M | 640 | 16% | N/A | N/A |
#10 | $18.7M | 93 | 21% | N/A | N/A |
What Is Alpharma?
N/A
Total Funding
707
Number of Employees
$142.1M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alpharma News
2022-04-20 - Canine Parvovirus Enteritis Key Companies, Drivers ...
Alpharma Animal Health, Ceva, Novasep, BASF SE, Bayer AG, Boehringer Ingelheim International GmbH, DSM, Elanco, Zoetis and others.
2022-04-19 - Feed Chlortetracycline Market 2022 Global Regional Outlook ...
Product Application. Livestock; Poultry; Aquaculture. Key competitor. Jinhe Biotechnology; Huazhong Chia Tai; Alpharma; PuCheng Chia Tai Biochemical.
2022-04-17 - Aquaculture Therapeutics Market Size, Scope And Forecast ...
TunaTech GmbH, ViAqua Therapeutics Ltd., Alpharma Inc., Blue Ridge Aquaculture, Cermaq ASA, Cooke Aquaculture, Nireus Aquaculture S.A., Tassal group Ltd.,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $452.6M | 1507 | 22% | $908M |
#2 | $280.2M | 1507 | 17% | $908M |
#3 | $540.1M | 1543 | 13% | N/A |
#4 | $672.8M | 1780 | -2% | N/A |
#5 | $769.5M | 1993 | 10% | $1.3M |